Post-earnings recap
Reported
Thu, Nov 5, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a narrower loss per share than expected, which is a positive sign for investors. However, the stock fell by 0.4% following the earnings report, indicating that investors may have been looking for more concrete guidance or revenue figures. The lack of revenue data and future guidance may have contributed to the stock's slight decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.06 | N/A | +79.87% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about the company's pipeline developments. However, they did not provide any specific guidance for future performance.
Management highlighted ongoing progress in their pipeline.
They emphasized the importance of upcoming clinical trials.
No specific guidance was provided for future quarters.